All In Biotech

Drug Trial Radar · NCT05130970

Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Garadacimab in Subjects With Idiopathic Pulmonary Fibrosis

Last checked: Nov 20, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

81

Actual

Start

Feb 3, 2022

Primary completion

Jan 2, 2024

Study completion Jan 2, 2024

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Nov 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of garadacimab in subjects with idiopathic pulmonary fibrosis (IPF).

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • GaradacimabDrug

    Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.

  • PlaceboDrug

    Participants received a matching placebo IV loading dose, followed by 3 SC doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent (TE) Serious Adverse Events (SAEs)Time frame: Up to 22 weeks
  2. Percentage of Participants With TE SAEsTime frame: Up to 22 weeks
  3. Number of Participants With TE Adverse Events of Special Interests (AESIs)Time frame: Up to 22 weeks
  4. Percentage of Participants With TE-AESIsTime frame: Up to 22 weeks
  5. Number of Participants With Garadacimab Induced Anti Drug Antibodies (ADAs) in PlasmaTime frame: At Day 36 and Day 92 after the first treatment
  6. Percentage of Participants With Garadacimab Induced ADAs in PlasmaTime frame: At Day 36 and Day 92 after the first treatment
  7. Number of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as Adverse Events (AEs)Time frame: Up to 14 weeks after treatment
  8. Percentage of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as AEsTime frame: Up to 14 weeks after treatment

Locations

47 sites in 11 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • Pulmonary Associates Clinical Trials AZ

    Phoenix, Arizona

  • National Institute of Clinical Research

    Huntington Beach, California

  • University of Southern California - Center for Advanced Lung Disease

    Los Angeles, California

  • University of California Irvine

    Orange, California

  • Meris Clinical Research

    Brandon, Florida

  • Reliant Medical Research

    Miami, Florida

  • US Associates in Research LLC

    Miami, Florida

  • Lakes Research

    Miami Lakes, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Central Florida Pulmonary Group, PA

    Orlando, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Jadestone Clinical Research

    Silver Spring, Maryland

  • Hannibal Clinic

    Hannibal, Missouri

  • Weill Cornell Medical Center

    New York, New York

  • Superior Clinical Research

    Smithfield, North Carolina

  • Southeastern Research Center

    Winston-Salem, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Temple University TMS

    Philadelphia, Pennsylvania

  • Clinical Trial Center of Middle Tennesse

    Franklin, Tennessee

  • Elite Medical Research

    Dallas, Texas

  • Southwest Family Medicine Associates

    Dallas, Texas

  • Baylor Scott and White Health - Advanced Lung Disease Specialists

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Medizinische Univerität Graz

    Graz, Austria

  • Kepler Universitätsklinikum

    Linz, Austria

  • Universitair Ziekenhuis (UZ) Leuven

    Leuven, Belgium

  • Centre Hospitalier Universitaire Sart Tilman

    Liège, Belgium

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, Canada

  • Dr. Syed Anees Medicine Professional Corporation

    Windsor, Ontario, Canada

  • Odense Universitetshospital - Lungemedicinsk Forskningsenhed

    Odense, Denmark

  • Fachkrankenhaus Coswig GmbH

    Coswig, Germany

  • Universitaetsklinikum Essen - Ruhrlandklinik (Westdeutsches Lungenzentrum)

    Essen, Germany

  • Medizinische Hochschule Hannover - Klinik für Pneumologie

    Hanover, Germany

  • Petrus Krankenhaus Wuppertal

    Wuppertal, Germany

  • Azienda Ospedaliera Universitaria Ospedali Riuniti Foggia

    Foggia, Italy

  • Centrum Medycyny Oddechowej Bialymstoku

    Bialystok, Poland

  • Twoja Przychodnia Centrum Medyczne Nowa Sol

    Nowa Sól, Poland

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.